Genetic testing for immune disorders
Official title: NIAID Centralized Sequencing Protocol
Run by National Institutes of Health Clinical Center (CC) · NCT03206099 · Data updated 2026-11-12
This study is testing how genetic factors affect immune disorders by looking at samples from people already involved in other research, to help improve care and understanding of these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Day to 100 Years |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 2 sites (Washington D.C., District of Columbia and 1 other locations) |
| Status | Recruiting |
| Started | July 31, 2017 |
| Main results expected | July 1, 2042 |
| Study ends | July 1, 2042 |
| Registry record updated | November 2, 2026 |
| Trial ID | NCT03206099 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 0-99 years who are participants in other NIH protocols and are willing to undergo genetic testing.
✕Probably not a fit
Patients who are not enrolled in NIH research protocols or those unwilling to provide biological samples for testing may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on understanding the genetic factors contributing to immune disorders through next-generation sequencing technologies. Participants, who are already involved in other NIH research protocols, will provide biological samples for genetic analysis. The research aims to enhance clinical care and improve the understanding of genetic variations related to immune diseases. By systematically collecting and analyzing genomic data, the study seeks to uncover insights into immune regulation and host defense mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment options for patients with immune disorders.
How similar studies have gone: Other studies utilizing genetic sequencing for understanding immune disorders have shown promise, indicating that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Must fulfill one of the following criteria: * Proband participants: must be individuals under investigation by another NIH protocol on which they are co-enrolled, or are referred from the GDMCC protocol "Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults" (NCT04702243) or "Use of Tiered Genetic Sequencing and Specialty Referral for Identifying and Managing Rare Genetic Causes of Chronic Suppurative Respiratory Disease" (External study #: 26-1761). Probands may have a disease under investigation or be healthy volunteers. * Biological relatives: biologically related to a proband participant. * Aged 0-99 years. * Participants must be willing to undergo genetic testing. * Participants must be willing to allow samples to be stored for future research. * Participants must be willing to have their de-identified genomic data shared, for example in a controlled access databases like the Database of Genotypes and Phenotypes (dbGaP). * To complete surveys and interviews: * Proficient with the English language. * Able to provide informed consent. * Adult healthy volunteers must be able to provide informed consent. EXCLUSION CRITERIA: Any condition that, in the opinion of the investigator, contraindicates participation in this study is a reason for exclusion.
Where it's running
-
Children's National Health System
Washington D.C., District of Columbia, United States Recruiting -
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Morgan N Similuk — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Morgan N Similuk
- Email: morgan.similuk@nih.gov
- Phone: (301) 435-6691
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Identifying autoantibodies before immune therapy for cancer
This study is testing if certain antibodies in the blood can help predict if cancer patients will have side effects from immune therapy and how well the treatment might work for them.
-
Evaluating endomyocardial biopsy and tailored treatments for pediatric inflammatory heart disease
This study is testing how a heart tissue sample and personalized treatments can help kids with inflammatory heart disease, especially those with myocarditis and heart rhythm issues.
-
Improving blood sugar and reducing inflammation through diet changes.
This study is testing whether a gluten-free diet and probiotics can help improve blood sugar levels and reduce inflammation in healthy people, including those with and without diabetes.
-
Using omalizumab to prevent asthma exacerbations in children
This study is testing if a single dose of omalizumab can help children aged 6-17 with asthma avoid worsening symptoms during colds and infections.
-
Exploring immune responses in diseases like psoriasis and eczema
This study is trying to see how the immune system works in people with psoriasis and eczema, as well as healthy volunteers, to better understand their skin healing and find new treatment options.
-
Evaluating endomyocardial biopsy and tailored treatments for inflammatory heart disease
This study is trying to see if a heart tissue test and personalized treatments can help people with inflammatory heart disease, especially those with myocarditis and heart rhythm issues.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.